国际妇产科学杂志
國際婦產科學雜誌
국제부산과학잡지
JOURNAL OF INTERNATIONAL OBSTETRICS AND GYNECOLOGY
2015年
4期
477-480
,共4页
恶性黑色素瘤%宫颈%免疫组化
噁性黑色素瘤%宮頸%免疫組化
악성흑색소류%궁경%면역조화
Malignant melanoma%Cervix%Immunohistochemistry
目的：探讨原发性宫颈恶性黑色素瘤的临床病理特征、治疗及预后。方法：对2002—2012年中国人民解放军总医院收治的4例原发性宫颈恶性黑色素瘤患者的临床病理资料进行回顾性分析，4例均进行随访。所有病理标本均进行免疫组化测定。结果：4例患者中1例为国际妇产科联盟（FIGO）分期Ⅰb1期，1例为Ⅱa期，2例为Ⅲa期。免疫组化检测：4例患者抗黑色素瘤特异性抗体（HMB45）、S-100均为阳性，3例Vimetin阳性，2例Melan-A阳性。4例患者均行手术治疗，2例辅以术后化疗，1例辅以术后放疗。3例患者因术后复发及转移分别存活6，25，40个月后死亡，1例患者术后随访34个月，至今仍无瘤存活。结论：原发性宫颈恶性黑色素瘤预后差，确诊需行病理检查及免疫组化检测且排除全身其他部位黑色素瘤，临床采用FIGO分期，治疗规范尚未确立，目前手术是主要的治疗手段。
目的：探討原髮性宮頸噁性黑色素瘤的臨床病理特徵、治療及預後。方法：對2002—2012年中國人民解放軍總醫院收治的4例原髮性宮頸噁性黑色素瘤患者的臨床病理資料進行迴顧性分析，4例均進行隨訪。所有病理標本均進行免疫組化測定。結果：4例患者中1例為國際婦產科聯盟（FIGO）分期Ⅰb1期，1例為Ⅱa期，2例為Ⅲa期。免疫組化檢測：4例患者抗黑色素瘤特異性抗體（HMB45）、S-100均為暘性，3例Vimetin暘性，2例Melan-A暘性。4例患者均行手術治療，2例輔以術後化療，1例輔以術後放療。3例患者因術後複髮及轉移分彆存活6，25，40箇月後死亡，1例患者術後隨訪34箇月，至今仍無瘤存活。結論：原髮性宮頸噁性黑色素瘤預後差，確診需行病理檢查及免疫組化檢測且排除全身其他部位黑色素瘤，臨床採用FIGO分期，治療規範尚未確立，目前手術是主要的治療手段。
목적：탐토원발성궁경악성흑색소류적림상병리특정、치료급예후。방법：대2002—2012년중국인민해방군총의원수치적4례원발성궁경악성흑색소류환자적림상병리자료진행회고성분석，4례균진행수방。소유병리표본균진행면역조화측정。결과：4례환자중1례위국제부산과련맹（FIGO）분기Ⅰb1기，1례위Ⅱa기，2례위Ⅲa기。면역조화검측：4례환자항흑색소류특이성항체（HMB45）、S-100균위양성，3례Vimetin양성，2례Melan-A양성。4례환자균행수술치료，2례보이술후화료，1례보이술후방료。3례환자인술후복발급전이분별존활6，25，40개월후사망，1례환자술후수방34개월，지금잉무류존활。결론：원발성궁경악성흑색소류예후차，학진수행병리검사급면역조화검측차배제전신기타부위흑색소류，림상채용FIGO분기，치료규범상미학립，목전수술시주요적치료수단。
Objective:To study the clinical presentation,pathological features,treatment and prognosis of primary malignant melanoma (MM) of the uterine cervix. Methods:The clinical and pathological date of four patients with primary cervical MM of PLA General Hospital from 2002 to 2012 were analyzed retrospectively. Their follow-up records were all reviewed. Results:One patient of primary cervical MM were diagnosed FIGO stageⅠb1,one was FIGO stageⅡa, two patients was FIGO StageⅢa. S-100 protein and HMB45 were positive in the four patients. Vimentin was positive in three of the patients. Melan-A was positive in two of the patients. The four patients all underwent surgical treatment. Two of them used chemotherapy and one used radiation as postoperative adjuvant therapy. One patient died 6 months and one died 40 months for metastasis. One patient died 25 months because of recurrence. One patient has survived for 34 months until now without metastasis and recurrence . Conclusions:Primary cervical MM is a extremely rare neoplasm with poor prognosis. The diagnosis is confirmed by histological examination and immunohistochemical study with exclusion of other sites of melanoma. Standardized treatment is not well established to date. The most popular treatment mode appears to be radical hysterectomy.
